Skip to content
image 35 image 35

Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) Analysis

Analyze circulating tumor cells and genomic material in blood as a non-invasive approach to study tumor biology Contact us

Liquid biopsy, including analysis of CTCs and cell free DNA in blood, can provide a more easily accessible way to obtain information of processes in other areas of the body, compared to tissue biopsies.

These liquid biopsy products can serve as potential biomarkers for indications of status, origin, progression and treatment response. However, found in low concentrations, with rare mutations, or in a fragmented condition, you need reliable tools that give you confidence in the signal you detect, followed by the appropriate downstream platform for analysis.

Precision specializes in developing approaches and technologies to maximize the biomarker information available from limited liquid biopsy samples.

 

Gain molecular insights from your liquid biopsy products

Leverage a suite of platform technologies into optimized workflows for detailed analysis of CTCs and cell-free nucleic acids which result in high specificity, superior recovery rates, and enhanced purity, so you can focus on your clinical end points. 

  • circulating-tumor-cells

    CTCs

    Analyze CTCs to gain information about the underlying status of the cancer:

    • Multiple DNA abnormalities
    • CTC numbers
    • RNA expression and fusion transcripts
    • Protein expression
    • In vitro/in vivo culture
  • auto-dna-purification

    cfDNA

    Elevated in certain disease process like inflammatory conditions and cancers, cfDNA genomic sequences can provide insight on cancer type by revealing:

    • Amplification and deletions
    • Translocations
    • Point mutations
    • Chromosomal abnormalities
    • Number of mutant molecules

Analyze with a full suite of downstream assays

Precision's optimized workflows allow for the most relevant enriched populations to be further characterized. Our multi-platform approach supports complex development programs, including immuno-oncology, autoimmune, and neurology therapeutic development.
  • Targeted NGS

    Targeted NGS

    Targeted NGS for genomic profiling

    Enable comprehensive genomics profiling with cancer-specific panels capable of detecting key immuno-oncology gene signatures (TMB, MSI) plus all main variant classes.
  • Gene expression

    Gene expression

    Gene expression with ddPCR

    Detect and discover biomarkers with high analytical specificity and sensitivity using ddPCR technology.
  • Single-cell

    Single-cell

    Single-cell sequencing

    Study the whole transcriptome, targeted gene expression, or perform multiomic profiling to look at cell surface proteins of interest.
  • mIF

    mIF

    Quantitative multiplex immunofluorescence (mIF)

    Concurrently visualize biomarkers to view various protein expressions in a sample. Prequalified IF panels targeted to a selection of different cancer types can deliver cytology information.
  • FISH / ISH

    FISH / ISH

    Fluorescence in situ hybridization

    Detect cellular genetic aberrations (multiploidy, translocations, and more) with custom FISH probes, commercially available FISH assays, or proprietary disease-specific FISH panels.

End-to-end liquid biopsy solutions from sample collection through data analysis and interpretation

assays

Collect and stabilize

Custom kitting with specialized collection tubes paired with shipping logistics expertise and real-time tracking

assays

Prep your samples

Standard workflows with robust QC for nucleic acid or cell extraction.

assays

For CTCs, enrich

Enrich CTCs with dedicated, in-house instruments for greater abundance

Choose the right assay for your endpoint

Consult with Precision experts to select the appropriate assay for what you're studying

assays

Analyze and discover

Follow robust, streamlined protocols for each assay type and visualize your data

ApoStream-ADAPT-2012-10

Enrich limited CTCs from precious blood samples

Precision has been a pioneer in liquid biopsy analysis of CTCs using our proprietary ApoStream technology for CTC capture.

Explore Apostream
iStock-1373474629 (1)

Skip the draw and start with research-ready, cell-free DNA (cfDNA)

Custom liquid biopsy specimens with deep characterizations, supported by custom kit design and distribution to fit any project requirements.

  • Oncology, immunology, and cardiology indications
  • Matched surgical biopsies (FNA, FFPE or Fresh Frozen)
  • Healthy and at-risk controls (age / gender matched)
  • Pre-treatment, post-treatment
  • Longitudinal (serial) collections
Learn about our liquid biopsy biospecimens

Proven Results

  • Whitepaper

    Guide to Liquid Biopsy

    Guide to Liquid Biopsy
  • Whitepaper

    Developing a comprehensive biomarker strategy for neurology therapeutic development

    Download Whitepaper
    Developing a comprehensive biomarker strategy for neurology therapeutic development
  • Whitepaper

    Guide to Immune Monitoring

    Download Whitepaper
    Guide to Immune Monitoring

Frequently Asked Questions

How do CTCs form?

As a tumor grows, cancer cells along the edges of the tumor migrate into the bloodstream and circulate through both the blood and lymphatic system as CTCs (also known as metastasis). These CTCs, present in approximately 1-100 cells in 5 million RBCs, can continue in circulation, join with other circulating tumor cells, or become lodged in outlying tissues to form additional tumors. When captured and concentrated, these CTCs can then be analyzed, providing information about the underlying status of a disease. Significantly, this liquid biopsy process is much less invasive to the patient than a traditional surgical biopsy.

Global coverage_Connections

Conduct multi-site trials globally

Our liquid biopsy analysis services support pre-clinical and clinical research, including multi-site studies, conducted anywhere in the world.

Our global sample processing and logistical network helps ensure the integrity of samples and the consistency of sample analysis data.

Collaborate with Precision for a personalized plan

Precision’s specialty lab scientists take a collaborative and consultative approach to projects and can provide recommendations on biomarker assay strategies.

Services can be provided individually or as part of a comprehensive therapeutic development package including biomarker assays and clinical trials.

Enhance your results with complementary platforms

  • ApoStream®: CTC Liquid Biopsy

    Proprietary Precision technology for antibody-free isolation and concentration of target cells in liquid biopsy samples; enables analysis via methods including mIF, FISH, and NGS
    Explore
  • Genomics Services

    With NGS, NanoString, qPCR and ddPCR capabilities, we can add insights from genomic and transcriptomic technologies to your understanding of patient biology.
    Explore
  • Multiplex Immuno-fluorescence

    Automated multiplex immunofluorescence services that enable quantitative visualization of up to 9 markers in tissue and liquid biopsies
    Explore